Valion Bio unit Velocity Bioworks completes initial feasibility test of LarmorBio BioScan-NMR platform

Valion Bio, Inc.

Initial evaluation found a strong correlation between BioScan-NMR signal and optical density at 600 nm (OD600), a common measure of cell density in liquid cultures.
Milestone came less than six months after Valion Bio secured exclusive rights to LarmorBio's next-generation NMR technology.
Platform is being developed as process analytical technology to track cell size, density, viability and phenotype inside bioreactors via continuous, non-invasive closed-system monitoring.
Interim CEO Dean Zikria called it an 'early-stage proof-of-concept' with encouraging results; Velocity Bioworks will use the data to guide further development of continuous monitoring.
Stated goals include earlier detection of process deviations, fewer batch failures and lower manufacturing costs; no financial terms, revenue or timelines disclosed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.